GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » China National Accord Medicines Corp Ltd (SZSE:000028) » Definitions » Change In Receivables

China National Accord Medicines (SZSE:000028) Change In Receivables : ¥0 Mil (TTM As of Mar. 2024)


View and export this data going back to 1993. Start your Free Trial

What is China National Accord Medicines Change In Receivables?

China National Accord Medicines's change in receivables for the quarter that ended in Mar. 2024 was ¥0 Mil. It means China National Accord Medicines's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

China National Accord Medicines's change in receivables for the fiscal year that ended in Dec. 2023 was ¥-3,992 Mil. It means China National Accord Medicines's Accounts Receivable increased by ¥3,992 Mil from Dec. 2022 to Dec. 2023 .

China National Accord Medicines's Accounts Receivable for the quarter that ended in Mar. 2024 was ¥22,990 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. China National Accord Medicines's Days Sales Outstanding for the three months ended in Mar. 2024 was 109.89.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. China National Accord Medicines's liquidation value for the three months ended in Mar. 2024 was ¥-3,018 Mil.


China National Accord Medicines Change In Receivables Historical Data

The historical data trend for China National Accord Medicines's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China National Accord Medicines Change In Receivables Chart

China National Accord Medicines Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -793.31 -2,989.96 -2,120.78 1,227.01 -3,992.43

China National Accord Medicines Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

China National Accord Medicines Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China National Accord Medicines  (SZSE:000028) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

China National Accord Medicines's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=22990.158/19090.481*91
=109.89

2. In Ben Graham's calculation of liquidation value, China National Accord Medicines's accounts receivable are only considered to be worth 75% of book value:

China National Accord Medicines's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=5723.4-30106.181+0.75 * 22990.158+0.5 * 8244.604
=-3,018

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China National Accord Medicines Change In Receivables Related Terms

Thank you for viewing the detailed overview of China National Accord Medicines's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


China National Accord Medicines (SZSE:000028) Business Description

Traded in Other Exchanges
Address
No. 15, Ba Gua Si 4th Road, Accord Pharmaceutical Building, Futian District, Guangdong Province, Shenzhen, CHN, 518029
China National Accord Medicines Corp Ltd develops and manufactures pharmaceuticals in China. The company engaged in the wholesale of Chinese patent drugs, traditional Chinese medicines, chemical medicine preparations, antibiotics, biochemical drugs and cerebrovascular system drugs. It operates through the following segments: The Head office segment engages in investing and managing the business; The Pharmaceutical Distribution segment engages in the distribution of medicine and pharmaceutical products to customers, including hospitals, other distributors, retail drug stores, and clinics, and Retail pharmacy segment, which is managing the operation of Guoda Pharmacy. It generates maximum revenue from the Pharmaceutical Distribution segment.

China National Accord Medicines (SZSE:000028) Headlines

No Headlines